IL162109A0 - The use of anti-histaminics for acute reduction ofelevated intracranial pressure - Google Patents

The use of anti-histaminics for acute reduction ofelevated intracranial pressure

Info

Publication number
IL162109A0
IL162109A0 IL16210902A IL16210902A IL162109A0 IL 162109 A0 IL162109 A0 IL 162109A0 IL 16210902 A IL16210902 A IL 16210902A IL 16210902 A IL16210902 A IL 16210902A IL 162109 A0 IL162109 A0 IL 162109A0
Authority
IL
Israel
Prior art keywords
intracranial pressure
brain injury
ofelevated
histaminics
traumatic
Prior art date
Application number
IL16210902A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL162109A0 publication Critical patent/IL162109A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16210902A 2001-11-23 2002-11-22 The use of anti-histaminics for acute reduction ofelevated intracranial pressure IL162109A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204574 2001-11-23
PCT/EP2002/013180 WO2003044023A1 (en) 2001-11-23 2002-11-22 The use of anti-histaminics for acute reduction of elevated intracranial pressure

Publications (1)

Publication Number Publication Date
IL162109A0 true IL162109A0 (en) 2005-11-20

Family

ID=8181317

Family Applications (4)

Application Number Title Priority Date Filing Date
IL16210902A IL162109A0 (en) 2001-11-23 2002-11-22 The use of anti-histaminics for acute reduction ofelevated intracranial pressure
IL162109A IL162109A (en) 2001-11-23 2004-05-20 Use of anti-histaminics for acute reduction of elevated intracranial pressure
IL188457A IL188457A (en) 2001-11-23 2007-12-27 Use of anti-histaminics for acute reduction of elevated intracranial pressure
IL194992A IL194992A (en) 2001-11-23 2008-10-30 Compound, pharmaceutical composition comprising the same, process for preparing the same and use thereof for preparation of medicaments for acute reduction of elevated intracranial pressure

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL162109A IL162109A (en) 2001-11-23 2004-05-20 Use of anti-histaminics for acute reduction of elevated intracranial pressure
IL188457A IL188457A (en) 2001-11-23 2007-12-27 Use of anti-histaminics for acute reduction of elevated intracranial pressure
IL194992A IL194992A (en) 2001-11-23 2008-10-30 Compound, pharmaceutical composition comprising the same, process for preparing the same and use thereof for preparation of medicaments for acute reduction of elevated intracranial pressure

Country Status (26)

Country Link
US (1) US7732437B2 (ru)
EP (2) EP1451196B1 (ru)
JP (2) JP4505226B2 (ru)
KR (1) KR100967601B1 (ru)
CN (2) CN100478031C (ru)
AT (2) ATE370149T1 (ru)
AU (1) AU2002356715B2 (ru)
CA (2) CA2467097C (ru)
CY (2) CY1107472T1 (ru)
DE (2) DE60231351D1 (ru)
DK (2) DK1451196T3 (ru)
ES (2) ES2290364T3 (ru)
HK (2) HK1073309A1 (ru)
HR (1) HRP20040427B1 (ru)
HU (1) HU229118B1 (ru)
IL (4) IL162109A0 (ru)
MX (1) MXPA04004867A (ru)
NO (1) NO333656B1 (ru)
NZ (2) NZ550723A (ru)
PL (1) PL209953B1 (ru)
PT (2) PT1451196E (ru)
RU (1) RU2311418C2 (ru)
SI (2) SI1451196T1 (ru)
UA (1) UA76803C2 (ru)
WO (1) WO2003044023A1 (ru)
ZA (1) ZA200403923B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1451196T3 (da) 2001-11-23 2007-11-12 Janssen Pharmaceutica Nv Anvendelse af substituerede tetracykliske imidazolderivater som antihistaminstoffer
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
EP2796683A4 (en) * 2011-12-20 2015-05-20 Toyota Motor Co Ltd ERROR DETECTION DEVICE FOR AN ELECTRICALLY HEATABLE CATALYST
US9717726B2 (en) * 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
EP3558296B1 (en) 2016-12-23 2023-06-28 Maregade RX, LLC Low dose product and method for treating diarrhea
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595988A (en) * 1992-12-04 1997-01-21 Janssen Pharmaceutica N.V. Triazolo(pyrrolo, thieno or furano)azepine derivatives
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
EP1011726B1 (en) * 1997-09-18 2003-02-26 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
EP1401838B1 (en) * 2001-06-12 2014-03-26 Janssen Pharmaceutica NV Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
DK1451196T3 (da) 2001-11-23 2007-11-12 Janssen Pharmaceutica Nv Anvendelse af substituerede tetracykliske imidazolderivater som antihistaminstoffer

Also Published As

Publication number Publication date
SI1832287T1 (sl) 2009-06-30
DE60221891T2 (de) 2008-05-08
DE60221891D1 (de) 2007-09-27
MXPA04004867A (es) 2004-07-30
CY1107472T1 (el) 2012-12-19
EP1451196A1 (en) 2004-09-01
EP1832287A3 (en) 2007-12-26
IL194992A (en) 2010-12-30
IL188457A (en) 2010-11-30
SI1451196T1 (sl) 2007-12-31
NO333656B1 (no) 2013-08-05
ATE370149T1 (de) 2007-09-15
EP1832287A2 (en) 2007-09-12
IL188457A0 (en) 2008-03-20
ES2290364T3 (es) 2008-02-16
EP1451196B1 (en) 2007-08-15
DE60231351D1 (de) 2009-04-09
RU2311418C2 (ru) 2007-11-27
NZ532718A (en) 2007-01-26
IL194992A0 (en) 2009-08-03
CN100478031C (zh) 2009-04-15
JP4505226B2 (ja) 2010-07-21
PL209953B1 (pl) 2011-11-30
WO2003044023A1 (en) 2003-05-30
HK1073309A1 (en) 2005-09-30
AU2002356715A1 (en) 2003-06-10
PT1832287E (pt) 2009-05-05
HRP20040427B1 (en) 2012-09-30
HRP20040427A2 (en) 2005-06-30
HU229118B1 (en) 2013-08-28
JP2009102417A (ja) 2009-05-14
DK1451196T3 (da) 2007-11-12
KR20050044328A (ko) 2005-05-12
AU2002356715B2 (en) 2008-05-15
JP4991770B2 (ja) 2012-08-01
CA2690483A1 (en) 2003-05-30
NO20042618L (no) 2004-06-22
CA2467097C (en) 2011-02-01
NZ550723A (en) 2008-06-30
CN100379744C (zh) 2008-04-09
EP1832287B1 (en) 2009-02-25
ATE423599T1 (de) 2009-03-15
JP2005509680A (ja) 2005-04-14
ZA200403923B (en) 2005-10-26
HK1101672A1 (en) 2007-10-26
US20050070525A1 (en) 2005-03-31
ES2321987T3 (es) 2009-06-15
DK1832287T3 (da) 2009-06-08
CA2467097A1 (en) 2003-05-30
CN1895673A (zh) 2007-01-17
CA2690483C (en) 2012-07-24
KR100967601B1 (ko) 2010-07-05
HUP0402357A2 (hu) 2005-02-28
CN1589273A (zh) 2005-03-02
UA76803C2 (ru) 2006-09-15
IL162109A (en) 2010-04-29
RU2004118838A (ru) 2005-04-10
CY1109108T1 (el) 2014-07-02
PL369864A1 (en) 2005-05-02
US7732437B2 (en) 2010-06-08
HUP0402357A3 (en) 2009-10-28
PT1451196E (pt) 2007-10-25

Similar Documents

Publication Publication Date Title
IL194992A0 (en) The use of anti-histaminics for acute reduction of elevated intracranial pressure
US20060110379A1 (en) Linkage of agents using microparticles
EP1054998A1 (en) Transglutaminase linkage of agents to tissue
ES2692151T5 (es) Espray de protección solar cosmético
WO2002098375A3 (en) Starch-oil composites for use in personal care applications
US20140093467A1 (en) Styling agents having maximum hold
ES2278092T3 (es) Emulsion de silicona en agua, que contiene un copolimero especifico de polieter-polidimetilsiloxano.
ATE471723T1 (de) Zusammensetzung zur ophthalmischen verwendung
DE60001232T2 (de) Hautreinigungsmittel
WO2003009819A3 (en) Temperature insensitive one-phase microemulsions
US20160074292A1 (en) Mineral salts for reducing the content of cysteic acid in keratin fibres
ES2673163T3 (es) Producto protector solar libre de agentes conservantes
CN112469819A (zh) 包括神经干细胞培养肉汤作为活性成分的用于抗衰老或减少皱纹的化妆品组合物和其制备方法
NO914781L (no) Kosmetisk rengjoeringsvaeske
ES2320104T3 (es) Metodo para la deformacion duradera de fibras que contienen queratina y producto correspondiente.
ES2759570T3 (es) Preparación cosmética que contiene ácido glicirrético
BR0314451A (pt) Composição lìquida de limpeza pessoal
US20170296444A1 (en) Cosmetic emulsion spray
JP2005526700A (ja) 清浄化調製物の選択性を得るためもしくは高めるためのアルキルグルコシドの使用
García Diagnosi delle malattie toraciche e addominali nei bovini con la sonda lineare transrettale: metodo BovATUS. Prima parte: lato sinistro.
Korte et al. S 2-42: Expression of CAP1 and CAP2 in developing and adult mouse tissues
WO2002031142A3 (en) Antisense nucleic acid against alphav integrin
WO2009136033A3 (fr) Utilisation cosmetique de proteines de type annexine ii pour le traitement de la secheresse cutanee
Реєст ARS cup-2010
Wang et al. Organization of satellite DNA in the genome of Trypanosoma cruzi MCQB Elias, NS Vargas, B. Zingales, S. Schenkman (Brazil) 1 Efficiency and specificity of RNA interference generated by intra-and intermolecular double stranded RNA in Trypanosoma brucei M. Durand-Dubief, L. Kohl, P. Bastin (France) 11 Gene discovery in the Entamoeba invadens genome